Earnings Call Summary | Champions Oncology(CSBR.US) Q4 2024 Earnings Conference
Earnings Call Summary | Champions Oncology(CSBR.US) Q4 2024 Earnings Conference
The following is a summary of the Champions Oncology, Inc. (CSBR) Q4 2024 Earnings Call Transcript:
以下是 Champions Oncology, Inc. (CSBR) 2024 年第四季度業績會交流摘要:
Financial Performance:
金融業績:
Champions Oncology reported fiscal year 2024 revenue of $15 million, a decline of $4 million or 7% year-over-year, leading to a larger net loss.
For Q4 of fiscal year 2024, revenue increased to $14 million, up from $13.1 million, with an increased gross margin in pharmacology services to 49%.
Reported a net loss from operations of $7.4 million for fiscal year 2024, and an adjusted EBITDA of approximately $900,000 for Q4, showing signs of financial recovery.
Champions Oncology 報告了 2024 財年 1500 萬元的營業收入,同比下降了 400 萬元或 7%,導致淨虧損進一步擴大。
2024財年第四季度,營業收入增至1400萬美元,較之1310萬美元有所提高,藥理服務的毛利率也提高至49%。
報告了 2024 財年運營淨虧損爲 740 萬元,以及第四季度調整後 EBITDA 約爲 90 萬美元,顯示出財務恢復的跡象。
Business Progress:
業務進展:
Champions Oncology is focusing on expanding relationships with big pharma customers and improving operational efficiencies to support revenue growth and cost management.
Development continues on the ex-Vivo platform, with a strategic key hire made to potentially increase its revenue contribution substantially.
Champions Oncology 正致力於擴大與大型製藥客戶的關係,並提高運營效率以支持營收增長和成本管理。
在智能外部平台方面,開發工作仍在進行中,並且已經招聘了關鍵人才,可能會大幅提高其收入貢獻。
Opportunities:
機會:
Strategic shift to focus more on large pharma customers provides both upside opportunity in robustness and resilience against sector downturns.
Optimism about increasing the contribution of the ex-Vivo platform to the company's revenue.
戰略轉移更多地關注大型製藥公司,爲行業低迷期提供了穩健性和彈性,具有上漲機會。
對智能外部平台增加公司營收的前景持樂觀態度。
Risks:
風險:
A weak biotech economic environment leading to reduced bookings growth and increased cancellations impacting revenue conversion.
疲弱的生物技術經濟環境導致預訂增長下降和取消增加,影響了收入的轉化。
More details: Champions Oncology IR
更多詳細信息請關注 Champions Oncology 投資人關係頁面。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息,請參閱IR網站。本文只是爲投資者提供參考,沒有任何指導或推薦建議。